ClinicalTrials.gg
Active, not recruitingNCT06996392Updated May 30, 2025

Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure

A Phase 1 interventional study of Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(4 hours) and Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(6 hours) in Acute-On-Chronic Liver Failure, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University — 6 open to participants now, 8 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Third Affiliated Hospital, Sun Yat-Sen University.

Planned enrollment
9th of 11
15 · median 60
Started
2025
the only one that year
Phase 1
3 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 11th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

6 of the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, or all of them as a file.
02

Study summary

The goal of this Phase I clinical trial is to evaluate the safety and efficacy of combining the QH-1A bioartificial liver device with mesenchymal stem cells(MSCs) for blood purification in treating patients with acute-on-chronic liver failure, and to determine the optimal treatment duration and frequency for Phase II. The study will enroll patients aged 18 to 65 years who meet the diagnostic criteria for acute-on-chronic liver failure as outlined in the 2024 Chinese Liver Failure Clinical Guidelines.

The main questions this study aims to answer are:

  • Does the combined therapy improve the 28-day survival rate after the final treatment?
  • Does the QH-1A device in its HBAL mode consistently achieve the predefined device performance pass rate?
  • Do patients show significant improvements in their biochemical markers following treatment?
  • What is the immunogenicity profile of the mesenchymal stem cells used for blood purification?

Participants will be screened within 14 days before their first treatment and will be allocated into one of four groups based on treatment duration and frequency:

  • 4-hour group (3 patients)
  • 6-hour group (3 patients)
  • 8-hour group (3 patients)
  • Multiple-treatment group (6 patients) Treatment will be administered in a sequential escalation-from the 4-hour group up to the multiple-treatment group-based on safety data from a 28-day observation period, which will be reviewed by a Safety Evaluation Committee. In addition, upon referral to the Hepatitis B Health Clinic, participants will receive tailored health education, comprehensive liver function and virological assessments, and an individualized treatment and follow-up plan.
03

Conditions studied

  • Acute-On-Chronic Liver Failure

Keywords

  • Acute -On-Chronic Liver Failure
  • Bio-artificial liver
  • Mesenchymal stem cells
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years, irrespective of gender.
  • Patients with acute-on-chronic liver failure, diagnosed according to the - - Guideline for diagnosis and treatment of liver failure (2024 version) in China.
  • Subjects must provide prior to the study and voluntarily sign the written informed consent form.
  • Subjects must be able to communicate effectively with the investigators and comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or disseminated intravascular coagulation (DIC) that is not effectively controlled.
  • Allergies to the blood products or medications used during treatment.
  • Circulatory failure.
  • Occurrence of myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months.
  • A history of malignant tumors within the past 5 years (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
  • Any other conditions that, in the opinion of the investigator, render the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    4-hour group

    The 4-hour group will receive a single biological artificial liver treatment for 4 hours (±15 minutes).

    Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(4 hours)

  • Experimental
    6-hour group

    The 6-hour group will receive a single biological artificial liver treatment for 6 hours (±15 minutes).

    Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(6 hours)

  • Experimental
    8-hour group

    The 8-hour group will receive a single biological artificial liver treatment for 8 hours (±15 minutes).

    Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(8 hours)

  • Experimental
    Multiple-treatment group

    The Safety Evaluation Committee will determine the maximum tolerable treatment duration based on the 28-day safety observation outcomes from the 4-, 6-, and 8-hour groups. This duration will then be adopted as the treatment time for the multiple-treatment group. Subjects in the multiple-treatment group will undergo 2-3 treatments at this maximum duration, with an interval of 3 (±1) days between sessions.

    Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(Multiple-treatment)

Interventions

  • Combination productCombining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(4 hours)

    The 4-hour group treatment session lasts 4 hours (±15 minutes). In the HBAL mode of the combined bioartificial liver device QH-1A, blood is initially filtered to separate the plasma, which is then pumped into a bioreactor. In this study, this bioreactor is uniquely filled with immortalized mesenchymal stem cells (PT-MSCs) optimized for blood purification. These cells are cultured to adhere to the outer surface of hollow fibers within the bioreactor, creating a stable and efficient living interface that continuously secretes bioactive factors such as exosomes.After passing through the bioreactor, the plasma is re-filtered and then returned to the patient's circulation via a dedicated pump.

  • Combination productCombining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(6 hours)

    After the three subjects in the 4-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 6-hour group.The 6-hour group treatment session lasts 6 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.

  • Combination productCombining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(8 hours)

    After the three subjects in the 6-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 8-hour group. The 8-hour group treatment session lasts 8 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.

  • Combination productCombining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(Multiple-treatment)

    Subjects in the multiple-treatment group will receive 2-3 sessions of bioartificial liver treatment; the number of sessions will be determined by the investigators based on the subjects' clinical needs. The treatment duration for each session will be set as the maximum tolerable period, as confirmed by the Safety Evaluation Committee based on 28-day safety observations from the 4-hour, 6-hour, and 8-hour groups. Each treatment session is administered following the procedure applied to patients in the group with the optimal tolerability duration.

06

What researchers measure

Primary outcomes

  1. Survival rate

    Time frame: 28-day

Secondary outcomes

  1. Combined Bioartificial Liver Device QH-1A Equipment Performance Pass Rate

    Pass Criteria: If all items on the trial medical device evaluation are rated as "Yes," the device's performance is deemed acceptable. If any evaluation item is rated as "No," the device's performance is considered unacceptable. Reasons for any "No" ratings must be documented.

    Time frame: Day 1

  2. Changes from the baseline in Child-Pugh grade

    The Child-Pugh classification evaluation indicators consist of hepatic encephalopathy, ascites, total bilirubin, albumin, and prolonged PT time. The scoring and classification of the severity of Child-Pugh liver diseases are as follows:Grade A is 5 to 6 points. Grade B is 7 to 9 points. Grade C is 10 to 15 points. The higher the score, the worse the liver function.

    Time frame: 28-day

  3. Changes from the baseline in COSSH-ACLF IIs

    The Chinese Severe Hepatitis B Study Group (COSSH), based on a multicenter, open-label large cohort study, has established a novel prognostic scoring system for hepatitis B virus (HBV)-ACLF: COSSH-ACLF II s. A score of less than 7.4 indicates a low-risk group, a score between 7.4 and 8.4 indicates a moderate-risk group, and a score greater than 8.4 indicates a high risk of 28- and 90-day mortality.

    Time frame: 28-day

  4. Changes from the baseline in MELD score

    The MELD score (Model for End-Stage Liver Disease) is a scoring system used to assess the urgency of liver transplantation in chronic liver disease patients. The MELD score typically ranges from 6 to 40, with higher scores indicating more severe disease and a greater need for liver transplantation.

    Time frame: 28-day

  5. The rate of bridging liver transplantation

    Time frame: 28-day

Other outcomes

  1. Incidence of adverse events and serious adverse events

    All treatment-related adverse events will be assessed by CTCAE v5.0.

    Time frame: 28-day

  2. Number of participants with positive infectious pathogens in the return fluid

    After each treatment session (0-15 minutes post-treatment), the return fluid from the bioreactor will be collected for testing of infectious pathogens (bacteria, fungi) and endotoxins.

    Time frame: Day1

  3. Number of participants with positive replicative lentivirus in the blood

    blood samples were collected for the detection of replicative lentivirus.

    Time frame: Day1,Day28

  4. Number of participants in whom mesenchymal stem cell shedding was detected in the return fluid

    During each treatment process, return fluid is collected at the front and back of the reactor at designated time points. Techniques such as flow cytometry and real-time fluorescence quantitative PCR are used to assess the shedding of mesenchymal stem cells.

    Time frame: Day1

  5. Changes from the baseline in immunogenicity indicators

    During the observational study, changes in immunogenicity indicators were monitored to evaluate the immunogenicity of the investigational product. The immunogenicity indicators included immunoglobulins (IgM, IgG, IgA, IgE), complements (C3, C4), lymphocyte subset analysis (CD3+ T cell count and percentage, CD4+ T cell count and percentage, CD8+ T cell count and percentage), and cytokines (IL-2, IL-6, IL-8, IL-10, TNF-α, IFN-γ). Blood samples were collected for immunogenicity assessment at the following time points: before each machine-based treatment (-30 min to 0 min), 7±1 days, 28±3 days.

    Time frame: Day1, Day7,Day28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
May 30, 2025
StartActual
May 7, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06996392
Collaborators
Guangdong Qianhui Biotechnology Co., Ltd
Responsible party
Liang Peng (Professor, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
May 30, 2025
Start date
May 7, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 30, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion